DAVENPORT & Co LLC Cuts Stock Holdings in Enovis Corporation $ENOV

Key Points

• DAVENPORT & Co LLC cut its Enovis stake by 13.1%, selling 367,689 shares and ending the quarter with 2,439,308 shares (about a 4.27% stake) valued at roughly $64.98 million.
• Insider Oliver Engert bought 1,000 shares at $25.50 on Feb. 27; insiders purchased 5,000 shares over the past 90 days and now own about 2.70% of the company.
• Analysts maintain an average Buy rating with a $47.43 average price target; Enovis recently beat EPS estimates and set FY2026 guidance of 3.520–3.730 EPS, with a market cap near $1.26 billion and a 52‑week range of $21–$40.69.

DAVENPORT & Co LLC lowered its holdings in Enovis Corporation (NYSE:ENOV - Free Report) by 13.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,439,308 shares of the company's stock after selling 367,689 shares during the quarter. DAVENPORT & Co LLC owned approximately 4.27% of Enovis worth $64,983,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Impax Asset Management Group plc lifted its holdings in Enovis by 47.5% during the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company's stock worth $9,425,000 after buying an additional 100,000 shares during the period. Capital Fund Management S.A. purchased a new position in shares of Enovis in the 2nd quarter valued at $1,682,000. Assenagon Asset Management S.A. bought a new position in shares of Enovis in the 3rd quarter worth $4,045,000. Osaic Holdings Inc. raised its position in shares of Enovis by 56.0% in the 2nd quarter. Osaic Holdings Inc. now owns 139,727 shares of the company's stock worth $4,382,000 after acquiring an additional 50,156 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Enovis by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company's stock worth $197,945,000 after purchasing an additional 125,460 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Insider Activity

In other news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider directly owned 43,640 shares of the company's stock, valued at approximately $1,112,820. The trade was a 2.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders acquired 5,000 shares of company stock valued at $121,983. 2.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Wall Street Zen lowered Enovis from a "buy" rating to a "hold" rating in a research note on Sunday. BTIG Research increased their price target on shares of Enovis from $41.00 to $43.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. Zacks Research upgraded shares of Enovis from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 4th. Canaccord Genuity Group cut their price objective on shares of Enovis from $58.00 to $50.00 and set a "buy" rating on the stock in a research report on Wednesday, December 17th. Finally, Needham & Company LLC boosted their price objective on shares of Enovis from $49.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $47.43.

Enovis Stock Performance

Shares of Enovis stock opened at $22.07 on Wednesday. The company has a 50 day moving average price of $23.12 and a 200 day moving average price of $27.36. The firm has a market capitalization of $1.26 billion, a P/E ratio of -1.07 and a beta of 1.46. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $40.69.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. Enovis's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.